fluoxetine has been researched along with Amphetamine-Related Disorders in 7 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Amphetamine-Related Disorders: Disorders related or resulting from use of amphetamines.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The symptom of "diminished interest or pleasure" in rewarding stimuli is an affective symptom of nicotine and amphetamine withdrawal, and a core symptom of depression." | 3.71 | Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. ( Harrison, AA; Liem, YT; Markou, A, 2001) |
| " Finally, the dopamine transporter inhibitor GBR 12909 completely prevented dopamine neurotoxicity caused by the malonate/MDMA combination and reversed the exacerbating toxic effects of malonate on MDMA-induced 5-HT depletion without significantly altering the hyperthermic response." | 1.33 | Studies on striatal neurotoxicity caused by the 3,4-methylenedioxymethamphetamine/ malonate combination: implications for serotonin/dopamine interactions. ( Aguirre, N; Goñi-Allo, B; Herv'as, I; Lasheras, B; Ramos, M, 2006) |
| "Fluoxetine treatment before both the conditioning and preference tests abolished METH CPP." | 1.33 | Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: studies in mice. ( Hagino, Y; Ikeda, K; Markou, A; Ogai, Y; Takamatsu, Y; Yamamoto, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ayala, ME | 1 |
| Liu, M | 1 |
| Wang, Y | 1 |
| Wang, HM | 1 |
| Bai, Y | 1 |
| Zhang, XH | 1 |
| Sun, YX | 1 |
| Wang, HL | 1 |
| Camacho, A | 1 |
| Stein, MB | 1 |
| Goñi-Allo, B | 1 |
| Ramos, M | 1 |
| Herv'as, I | 1 |
| Lasheras, B | 1 |
| Aguirre, N | 1 |
| Takamatsu, Y | 1 |
| Yamamoto, H | 1 |
| Ogai, Y | 1 |
| Hagino, Y | 1 |
| Markou, A | 2 |
| Ikeda, K | 1 |
| Batki, SL | 1 |
| Moon, J | 1 |
| Delucchi, K | 1 |
| Bradley, M | 1 |
| Hersh, D | 1 |
| Smolar, S | 1 |
| Mengis, M | 1 |
| Lefkowitz, E | 1 |
| Sexe, D | 1 |
| Morello, L | 1 |
| Everhart, T | 1 |
| Jones, RT | 1 |
| Jacob, P | 1 |
| Harrison, AA | 1 |
| Liem, YT | 1 |
1 trial available for fluoxetine and Amphetamine-Related Disorders
| Article | Year |
|---|---|
Methamphetamine quantitative urine concentrations during a controlled trial of fluoxetine treatment. Preliminary analysis.
Topics: Adult; Amphetamine-Related Disorders; Female; Fluoxetine; Humans; Male; Methamphetamine; Single-Blin | 2000 |
6 other studies available for fluoxetine and Amphetamine-Related Disorders
| Article | Year |
|---|---|
Brain serotonin, psychoactive drugs, and effects on reproduction.
Topics: Affect; Amphetamine-Related Disorders; Animals; Biological Clocks; Brain; Cognition Disorders; Depre | 2009 |
Fluoxetine attenuates chronic methamphetamine-induced pulmonary arterial remodelling: possible involvement of serotonin transporter and serotonin 1B receptor.
Topics: Amphetamine-Related Disorders; Animals; Antidepressive Agents, Second-Generation; Down-Regulation; F | 2013 |
Modafinil for social phobia and amphetamine dependence.
Topics: Amphetamine-Related Disorders; Benzhydryl Compounds; Central Nervous System Stimulants; Comorbidity; | 2002 |
Studies on striatal neurotoxicity caused by the 3,4-methylenedioxymethamphetamine/ malonate combination: implications for serotonin/dopamine interactions.
Topics: Amphetamine-Related Disorders; Animals; Body Temperature Regulation; Cell Survival; Corpus Striatum; | 2006 |
Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: studies in mice.
Topics: Amphetamine-Related Disorders; Animals; Dopamine Agents; Fluoxetine; Male; Methamphetamine; Mice; Mi | 2006 |
Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.
Topics: Aminopyridines; Amphetamine; Amphetamine-Related Disorders; Animals; Body Weight; Brain; Depression; | 2001 |